A role of P-glycoprotein in neurology

Chernykh I.V.; Shchulkin A.V.; Yakusheva E.N.; Popova N.M.

doi:https://doi.org/10.17116/jnevro20171171167-71

Close metadata

Recommended articles:

Neurobiological potential of astragaloside IV and prospects for its use in the treatment of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):7-12

Autonomic cardiovascular disorders in patients with epileptic and psychogenic non-epileptic seizures: a pilot study. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):13-20

Pathomorphosis of the Parkinson’s disease against the background of DBS STN. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):21-27

Cognitive vascular disorders and morphometric parameters of the prefrontal, dorsolateral cortex and thalamus in post-stroke patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):91-95

The effect of Mexidol on the level of neurogenesis markers in acute cerebrovascular accident in the experiment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):107-112

Asthenia in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):5-10

Effectiveness of comprehensive rehabilitation of patients after a stroke in terms of changes in clinical and functional characteristics. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):11-16

Methods for determining the extent of ischemic changes in brain matter in the prognosis of clinical outcome after successful thromboextraction. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):17-27

Confirmation of the competitive validity of the Russian Aphasiological Test, a new standardized tool for the diagnosis of aphasia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):28-34

Prevalence of cerebrovascular diseases risk factors according to the cohort survey data in Bishkek, Kyrgyz Republic. Russian Journal of Preventive Medicine. 2025;(3):34-39

Abstract:

On the basis of the analysis of literature data, the authors show a role of P-glycoprotein in the pathogenesis, pharmacotherapy and a prophylaxis of neurologic diseases (Alzheimer’s disease, Parkinson’s disease, epilepsy, stroke).

Keywords:

P-glycoprotein

ABCB1 protein

MDR1

Parkinson’s disease

epilepsy

stroke

Authors:

Chernykh I.V.

Ryazan State Medical University, Ryazan, Russia

Shchulkin A.V.

Ryazan State Medical University, Ryazan, Russia

Yakusheva E.N.

Ryazan State Medical University, Ryazan, Russia

Popova N.M.

Ryazan State Medical University, Ruazan, Russia

Close metadata

References:

Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell nutans. Biochem Biophis Acta. 1976;455(1):155-162. doi:10.1016/0005-2736(76)90160-7
Sharom FJ. The P-glycoprotein multidrug transporter. Essays Biochem. 2011;50:161-178. doi:10.1042/bse0500161
Lee CY, Lai TY, Wu YM, Hu RH, Lee PH, Hsu LC, Tsai MK. Gene Expression of P-glycoprotein and Cytochrome P450 3A4 in Peripheral Blood Mononuclear Cells and Correlation With Expression in Liver. Transplant Proc. 2010;42(3):834-836. doi:10.1016/j.transproceed.2010.02.048
Choi YH, Yu AM. ABC transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development. Curr Pharm Des. 2014;20:5:793-807.
Callen DF, Baker E, Simmers RN, Seshadri R, Robinson IB. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet. 1987;77:142-144. doi:10.1007/BF00272381
Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiot. 2008;8:7-8:802-832. doi:10.1080/00498250701867889
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Nat Acad Sci. 2000;97(7):3473-3478. doi:10.1073/pnas.050585397
Yakusheva EN, Shchulkin AV, Chernykh IV, Titov DS. Funkcional'naya aktivnost' glikoproteina-Р pri ehksperimental'nyh manipulyaciyah. Rossiyskiy mediko-biologicheskiy vestnik imeni akademika I.P. Pavlova. 2014;2:76-79.
Abuznait AH, Kaddoumi A. Role of ABC Transporters in the Pathogenesis of Alzheimer’s Disease. ACS chemical neuroscience. 2012;3:11:820-831. doi:10.1021/cn300077c
Kuwahara H, Nishida H, Yokota T. Blood-brain barrier and Alzheimer's disease. Brain Nerve. 2013;65:2:145-151.
Brenn A, Grube M, Jedlitschky G, Fischer A, Strohmeier B, Eiden M, Keller M, Groschup MH, Vogelgesang S. St. John's Wort reduces beta-amyloid accumulation in a double transgenic Alzheimer's disease mouse model-role of P-glycoprotein. Brain Pathol. 2014;24:1:18-24. doi:10.1111/bpa.12069
Deo AK, Borson S, Link JM, Domino K, Eary JF, Ke B, Richards TL, Mankoff DA, Minoshima S, O’Sullivan F, Eyal S, Hsiao P, Miravilla K, Unadkat JD. Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease. J Nucl Med. 2014;55:7:1106-1111. doi:10.2967/jnumed.113.130161
Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. The Journal of Clinical Investigation. 2005;115:6:1449-1457. doi:10.1172/JCI24761
Desai BS, Monahan AJ, Carvey PM, Hendey B. Blood—Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy. Cell Transplantation. 2007;16:3:285-299. doi:10.3727/000000007783464731
Kiyohara C, Miyake Y, Koyanagi M, Fujimoto T, Shirasawa S, Tanaka K, Fukushima W, Sasaki S, Tsuboi Y, Yamada T, Oeda T, Shimada H, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M, Kinki F. MDR1 C3435T Polymorphism and Interaction with Environmental Factors in Risk of Parkinson's Disease: A Case-control Study in Japan. Drug Metabolism and Pharmacokinetics. 2013;28:2:138-143. doi:10.2133/dmpk.DMPK-12-RG-075
Braakman HM, Vaessen MJ, Hofman PA, Debeijvan Hall MH, Backes WH, Vles JS, Aldenkamp AP. Cognitive and behavioral complications of frontal lobe epilepsy in children: a review of the literature. Epilepsia. 2011;52:849-856. doi:10.1111/j.1528-1167.2011.03057.x
Bankstahl JP, Hoffmann K, Bethmann K, Löscher W. Glutamate is critically involved in seizure-induced overexpression of P-glycoprotein in the brain. Neuropharmacology. 2008;54:6:1006-1016. doi:10.1016/j.neuropharm.2008.02.008
Gidal BE. P-glycoprotein Expression and Pharmacoresistant Epilepsy: Cause or Consequence? Epilepsy. 2014;14:3:136-138. doi:10.5698/1535-7597-14.3.136
Sun G, Sun X, Guan L. Association of MDR1 gene C3435T polymorphism with childhood intractable epilepsy: a meta-analysis. J Neural Transmis. 2011;121:7:717-724. doi:10.1007/s00702-014-1169-3
Haerian BS, Roslan H, Raymond AA, Tan CT, Lim KS, Zulkifli SZ, Mohamed EHM, Tan HJ, Mohamed Z. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: A systematic review and meta-analysis. Seizure. 2010;19:6:339-346. doi:10.1016/j.seizure.2010.05.004
Wei-Ping LV, Ren-Feng H, Zhi-Rong S. Associations between the C3435T polymorphism of the ABCB1 gene and drug resistance in epilepsy: a meta-analysis. Int J Clin Exp Med. 2014;7:11:3924-3932.
Li SX, Liu YY, Wang QB. ABCB1 Gene C3435T Polymorphism and Drug Resistance in Epilepsy: Evidence Based on 8604 Subjects. Med Sci Monit. 2015;21:861-868. doi:10.12659/MSM.894023
Cheng JW, Zhang LJ, Hou YQ, Zhao Q, Zhang XJ, Chen XF, Baihttp://www.sciencedirect.com/science/article/pii/S152550501400167X Y. Association between MDR1 C3435T polymorphism and refractory epilepsy in the Chinese population: A systematic review and meta-analysis. Epilepsy Behavior. 2014;36:173-179. doi:10.1016/j.yebeh.2014.05.007
Nicita F, Spalice A, Papetti L, Nikanorova M, Iannetti P, Parisi P. Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: A pilot study. Seizure. 2014;23:1:36-40. doi:10.1016/j.seizure.2013.09.009
Ji BS, Cen J, He L, Liu M, Liu YQ, Liu L. Modulation of P-glycoprotein in rat brain microvessel endothelial cells under oxygen glucose deprivation. J Pharm Pharmacol. 2013;65:10:1508-1517. doi:10.1111/jphp.12122
Spudich A, Kilic E, Xing H, Kilic U, Rentsch KM, Wunderli-Allenspach H, Bassetti CL, Hermann DM. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci. 2006;9:4:487-488. doi:10.1038/nn1676
Samoto K, Ikezaki K, Yokoyama N, Fukui M. P-glycoprotein expression in brain capillary endothelial cells after focal ischaemia in the rat. Neurol Res. 1994;16:3:217-223. doi:10.1007/978-3-7091-9334-1_68
Yano K, Takimoto S, Motegi T, Tomono T, Hagiwara M, Idota Y, Morimoto K, Takahara A, Ogihara T. Role of P-glycoprotein in regulating cilnidipine distribution to intact and ischemic brain. Drug Metab Pharmacokinet. 2014;29:3:254-258. doi:10.2133/dmpk.DMPK-13-RG-072
Belayev L, Busto R, Zhao W, Ginsberg MD. Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res. 1996;739:1-2:88-96. doi :10.1016/S0006-8993(96)00815-3
Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke W, Diener HC. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke. 2001;32:2559-2566. doi:10.1016/S0006-8993(96)00815-3
Stangier J, Clemens A. Pharmacology, pharmacokinetics and pharmacodynamics of dabigatran etexilate an oral direct thrombin inhibitor. Clin Appl Thromb/Hemost. 2009;15:9-16. doi:10.1177/1076029609343004
Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvänen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L. Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding. Circulation. 2013;127:1404-1412. doi:10.1161/CIRCULATIONAHA.112.001233
Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010;64:956-967. doi:10.1111/j.1742-1241.2009.02286.x
Härtter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75:4:1053-1062. doi:10.1111/j.1365-2125.2012.04453.x
Kubitza D, Becka M, Roth A, Mueck W. Absence of clinically relevant interactions between rivaroxaban — an oral, direct Factor Xa inhibitor--and digoxin or atorvastatin in healthy subjects. J Int Med Res. 2012;40:5:1688-1707. doi:10.1177/030006051204000508
Mendell J, Noveck RJ, Shi M. Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxinadministered alone and in combination. J Cardiovasc Pharmacol. 2012;60:4:335-341. doi:10.1097/FJC.0b013e31826265b6
Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, Zhang G, Shi M. Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor. Am J Cardiovasc Drugs. 2013; http://www.ncbi.nlm.nih.gov/pubmed/23784266. doi:10.1007/s40256-013-0029-0
Shchulkin A.V., Yakusheva E.N., Popova N.M. Rol' glikoproteina-P v racional'noj farmakoterapii v kardiologii. Racional'naya farmakoterapiya v kardiologii. 2013;9:6:687-693.